These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
786 related articles for article (PubMed ID: 32563561)
21. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Jiang YZ; Liu Y; Xiao Y; Hu X; Jiang L; Zuo WJ; Ma D; Ding J; Zhu X; Zou J; Verschraegen C; Stover DG; Kaklamani V; Wang ZH; Shao ZM Cell Res; 2021 Feb; 31(2):178-186. PubMed ID: 32719455 [TBL] [Abstract][Full Text] [Related]
22. State of art of advanced triple negative breast cancer. Khosravi-Shahi P; Cabezón-Gutiérrez L; Aparicio Salcedo MI Breast J; 2019 Sep; 25(5):967-970. PubMed ID: 31155832 [TBL] [Abstract][Full Text] [Related]
23. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon. Furlanetto J; Marmé F; Loibl S Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628 [TBL] [Abstract][Full Text] [Related]
24. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. Schreiber AR; Andress M; Diamond JR Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524 [No Abstract] [Full Text] [Related]
25. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967 [TBL] [Abstract][Full Text] [Related]
26. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. Mehlich D; Marusiak AA Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515 [TBL] [Abstract][Full Text] [Related]
27. Metastatic triple-negative breast cancer: Established and emerging treatments. Puri A; Reddy TP; Patel TA; Chang JC Breast J; 2020 Sep; 26(9):1793-1796. PubMed ID: 32578306 [TBL] [Abstract][Full Text] [Related]
28. Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer. Cipriano É; Mesquita A Breast Cancer (Auckl); 2021; 15():11782234211002491. PubMed ID: 33814914 [TBL] [Abstract][Full Text] [Related]
29. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725 [TBL] [Abstract][Full Text] [Related]
30. Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel? Bai X; Ni J; Beretov J; Graham P; Li Y Cancer Lett; 2021 Jan; 497():100-111. PubMed ID: 33069769 [TBL] [Abstract][Full Text] [Related]
31. The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials. Huynh MM; Pambid MR; Jayanthan A; Dorr A; Los G; Dunn SE Expert Opin Investig Drugs; 2020 Nov; 29(11):1199-1208. PubMed ID: 32869671 [TBL] [Abstract][Full Text] [Related]
32. Triple-Negative Breast Cancer: Breast Tumors With an Identity Crisis. Nunnery SE; Mayer IA; Balko JM Cancer J; 2021 Jan-Feb 01; 27(1):2-7. PubMed ID: 33475287 [TBL] [Abstract][Full Text] [Related]
33. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates]. Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340 [TBL] [Abstract][Full Text] [Related]
34. Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. Kagihara JA; Shagisultanova E; Afghahi A; Diamond JR Curr Breast Cancer Rep; 2021 Sep; 13(3):216-226. PubMed ID: 34457184 [TBL] [Abstract][Full Text] [Related]
35. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. Sharma P Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345 [TBL] [Abstract][Full Text] [Related]
36. Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer. Sayed-Ahmed MM; Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Aleisa AM; Al-Yahya AA; Alsheikh A; Al Diab AI; Al-Akeely MH Tumori; 2013; 99(4):545-54. PubMed ID: 24326846 [TBL] [Abstract][Full Text] [Related]
37. Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. Fremd C; Jaeger D; Schneeweiss A Expert Rev Anticancer Ther; 2019 Jan; 19(1):29-42. PubMed ID: 30351981 [No Abstract] [Full Text] [Related]
38. Triple-negative breast cancer: is there a treatment on the horizon? Yao H; He G; Yan S; Chen C; Song L; Rosol TJ; Deng X Oncotarget; 2017 Jan; 8(1):1913-1924. PubMed ID: 27765921 [TBL] [Abstract][Full Text] [Related]
39. Atezolizumab for the treatment of triple-negative breast cancer. Heimes AS; Schmidt M Expert Opin Investig Drugs; 2019 Jan; 28(1):1-5. PubMed ID: 30474425 [TBL] [Abstract][Full Text] [Related]
40. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy? Zangardi ML; Spring LM; Nagayama A; Bardia A Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]